Citadel Advisors
OBIO icon

Citadel Advisors’s Orchestra BioMed OBIO Stock Holding History

Citadel Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.2K Buy
+12,100
New +$49.5K ﹤0.01% 13095
2026
Q1 		– Sell
-24,200
Closed -$100K – 13844
2025
Q4 		$100K Buy
+24,200
New +$97.6K ﹤0.01% 11638

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Citadel Advisors's OBIO Position: Q2 2026 in Review

Citadel Advisors reduced its Orchestra BioMed (OBIO) stake by 29% in Q2 2026, selling an estimated $94K and leaving 56,191 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #11613.

Citadel Advisors first reported a position in OBIO in Q3 2020 and has held it in 22 quarters since. The position peaked at $3.34M in Q1 2023. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Citadel Advisors held 56,191 shares of Orchestra BioMed worth $242K as of Q2 2026.
  • Citadel Advisors sold 22,994 Orchestra BioMed shares in Q2 2026, an estimated $94K.
  • Orchestra BioMed made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11613 holding.
  • Citadel Advisors first reported a position in Orchestra BioMed in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Orchestra BioMed position peaked at $3.34M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.